Literature DB >> 25563139

Inflammatory bowel disease among Bedouin Arabs in southern Israel: urbanization and increasing prevalence rates.

Naim Abu Freha1, Doron Schwartz, Jaber Elkrinawi, Gil Ben Yakov, Muhammad Abu Tailakh, Daniela Munteanu, Abdelrhman Abu Ganim, Alexander Fich.   

Abstract

BACKGROUND AND AIM: Inflammatory bowel disease (IBD) has been associated with genetic and environmental factors, including urban living. IBD was rare in the Israeli Bedouin community 30 years ago. Over recent decades, a large proportion of this community has undergone a transition from a nomadic to a western lifestyle. Our aim was to carry out an updated evaluation of the clinical and epidemiological features of IBD in the Bedouin sector of southern Israel.
METHODS: All Bedouin patients with a known diagnosis of Crohn's disease (CD) or ulcerative colitis (UC) were included in the retrospective study.
RESULTS: The cohort included 31 CD patients and 31 UC patients. The mean age of the patients at diagnosis was 29±10.9 and 35±17.5 years for CD and UC, respectively. The prevalence rate for CD was 15.5/100,000 and the incidence rate was 0.8-3.55/100,000. Fourteen of the CD patients (45%) had ileal disease and 64.5% had inflammatory disease behavior according to the Montreal classification. Eleven of the CD patients (35%) were treated with anti-TNF-α and 26% had undergone surgery. Over the previous decade, the prevalence of UC was 14/100,000 and the incidence was 0.5-2.39/100,000. Eighteen UC patients (58%) had left-sided colitis. Three (9.7%) had undergone total colectomy for severe disease.
CONCLUSION: We found an increased prevalence of IBD in the Bedouin population, associated with their change in lifestyle over previous decades. However, the prevalence is still markedly lower than that in other population groups. A high percentage of patients were treated with anti-TNF-α and/or surgery.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25563139     DOI: 10.1097/MEG.0000000000000263

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  6 in total

1.  Liver Cirrhosis, Etiology and Clinical Characteristics Disparities Among Minority Population.

Authors:  Muhammad Abu Tailakh; Liat Poupko; Najwan Kayyal; Ali Alsana; Asia Estis-Deaton; Ohad Etzion; Alexander Fich; David Yardni; Naim Abu-Freha
Journal:  J Immigr Minor Health       Date:  2021-08-28

Review 2.  Glucocorticosteroid therapy in inflammatory bowel diseases: From clinical practice to molecular biology.

Authors:  Karen Dubois-Camacho; Payton A Ottum; Daniel Franco-Muñoz; Marjorie De la Fuente; Alejandro Torres-Riquelme; David Díaz-Jiménez; Mauricio Olivares-Morales; Gonzalo Astudillo; Rodrigo Quera; Marcela A Hermoso
Journal:  World J Gastroenterol       Date:  2017-09-28       Impact factor: 5.742

3.  A Systematic Review of Epidemiology and Risk Factors Associated With Chinese Inflammatory Bowel Disease.

Authors:  Guanglin Cui; Aping Yuan
Journal:  Front Med (Lausanne)       Date:  2018-06-19

Review 4.  Nutritional Modulation of Gene Expression: Might This be of Benefit to Individuals with Crohn's Disease?

Authors:  Lynnette R Ferguson
Journal:  Front Immunol       Date:  2015-09-11       Impact factor: 7.561

5.  ASCA and ANCA among Bedouin Arabs with inflammatory bowel disease, the frequency and phenotype correlation.

Authors:  Naim Abu-Freha; Wafi Badarna; Ina Sigal-Batikoff; Muhammad Abu Tailakh; Ohad Etzion; Jaber Elkrinawi; Arik Segal; Alex Mushkalo; Alex Fich
Journal:  BMC Gastroenterol       Date:  2018-10-20       Impact factor: 3.067

6.  Host immunoglobulin G selectively identifies pathobionts in pediatric inflammatory bowel diseases.

Authors:  Heather Armstrong; Misagh Alipour; Rosica Valcheva; Michael Bording-Jorgensen; Juan Jovel; Deenaz Zaidi; Prachi Shah; Yuefei Lou; Cory Ebeling; Andrew L Mason; Dawson Lafleur; Jeremy Jerasi; Gane K-S Wong; Karen Madsen; Matthew W Carroll; Hien Q Huynh; Levinus A Dieleman; Eytan Wine
Journal:  Microbiome       Date:  2019-01-03       Impact factor: 14.650

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.